Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 8/2019

01-08-2019 | Multiple Myeloma | Letter to the Editor

Intravenous busulfan plus melphalan versus melphalan alone as conditioning regimen for patients with multiple myeloma

Authors: M. Blanes, J. I. Lorenzo, P. Ribas, A. Jiménez, J. D. González, M. J. Cejalvo, C. Solano, A. Alegre, Javier de la Rubia

Published in: Annals of Hematology | Issue 8/2019

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Blanes M, de la Rubia J, Lahuerta JJ, González JD, Ribas P, Solano C, Alegre A, Sanz MA (2009) Single daily dose of intravenous busulfan and melphalan as a conditioning regimen for patients with multiple myeloma undergoing autologous stem cell transplantation: a phase II trial. Leuk Lymphoma 50:216–222CrossRefPubMed
2.
Lahuerta JJ, Martínez-López J, Grande C et al (2000) Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish Registry for Transplantation in multiple myeloma. Br J Haematol 109:138–147CrossRefPubMed
3.
4.
Ria R, Falzetti F, Ballanti S, Minelli O, di Ianni M, Cimminiello M, Vacca A, Dammacco F, Martelli MF, Tabilio A (2004) Melphalan versus melphalan plus busulphan in conditioning to autologous stem cell transplantation for low-risk multiple myeloma. Hematol J 5:118–122CrossRefPubMed
5.
Blanes M, Lahuerta JJ, González JD, Ribas P, Solano C, Alegre A, Bladé J, San Miguel JF, Sanz MA, de la Rubia J (2013) Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach. Biol Blood Marrow Transplant 19:69–74CrossRefPubMed
6.
Lahuerta JJ, Mateos MV, Martínez-López J et al (2010) Grupo Español de MM y Programa para el Estudio de la Terapéutica en Hemopatía Maligna Cooperative Study Groups. Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study. Haematol. 95:1913–1920CrossRef
7.
Jung SH, Lee JJ, Kim JS, Min CK, Kim K, Choi Y, Eom HS, Joo YD, Kim SH, Kwak JY, Kang HJ, Lee JH, Lee HS, Mun YC, Moon JH, Sohn SK, Park SK, Park Y, Shin HJ, Yoon SS, Korean Multiple Myeloma Working Party (2018) Korean Multiple Myeloma Working Party. Phase 2 study of an intravenous busulfan and melphalan conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma (KMM150). Biol Blood Marrow Transplant 24:923–929CrossRefPubMed
8.
Blanes M, González JD, Lahuerta JJ, Ribas P, Lorenzo I, Boluda B, Sanz MA, de la Rubia J (2015) Bortezomib-based induction therapy followed by intravenous busulfan-melphalan as conditioning regimen for patients with newly diagnosed multiple myeloma. Leuk Lymphoma 56:415–419CrossRefPubMed
9.
Rosiñol L, Oriol A, Ríos R, et al. Bortezomib, lenalidomide, and dexamethasone (VRD-GEM) as induction therapy prior to autologous stem cell transplantation (ASCT) in multiple myeloma: results of a phase III PETHEMA/GEM trial. 44th Annual meeting of the European Society for Blood and Marrow Transplantation, 2018, S003
Metadata
Title
Intravenous busulfan plus melphalan versus melphalan alone as conditioning regimen for patients with multiple myeloma
Authors
M. Blanes
J. I. Lorenzo
P. Ribas
A. Jiménez
J. D. González
M. J. Cejalvo
C. Solano
A. Alegre
Javier de la Rubia
Publication date
01-08-2019
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 8/2019
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-019-03663-5

Other articles of this Issue 8/2019

Annals of Hematology 8/2019 Go to the issue

Original Article

Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis

Letter to the Editor

Clinicohematologic and cytogenetic profile in a rare case of pure erythroid leukemia

Original Article

Allogeneic donor split skin grafts for treatment of refractory ulcers in cutaneous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation—a retrospective analysis on seven patients

Original Article

Ten-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real life

Letter to the Editor

Successful management of transcatheter aortic valve implantation by platelet transfusions in a nonagenarian patient with severe autoimmune factor V deficiency

Original Article

Clinical risk scores do not accurately identify a very high risk population with diffuse large B cell lymphoma—an analysis of 386 Portuguese patients
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits